Atlas Trials

Genfit

23 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Genfit

RecordFirmDate
Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients With Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure (NCT07694297)Genfit2026-10-01
Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers (NCT07110441)Genfit2025-08-26
A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy (NCT06987968)Genfit2025-08-25
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma (NCT05874414)Genfit2023-08-21
Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)® (NCT05900050)Genfit2023-07-02
Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects (NCT05368935)Genfit2022-04-25
Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients (NCT05116826)Genfit2021-11-05
Elafibranor Pharmacokinetic Parameters in Elderly Healthy Volunteers (NCT04171752)Genfit2019-11-22
Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin (NCT03985969)Genfit2019-09-23
Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL) (NCT03953456)Genfit2019-08-16
Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH) (NCT03883607)Genfit2019-06-25
Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients (NCT03844555)Genfit2019-02-28
Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients (NCT03765671)Genfit2018-12-12

Track Genfit automatically

Every clearance here is in the API, with alerts when new ones post.